Filing Flows › Ionis Pharmaceuticals (IONS) › Q4 2024
Ionis Pharmaceuticals (IONS) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 19, 2025
Ionis Pharmaceuticals (IONS) reported revenue of $227M for the fourth quarter 2024 (Q4 2024), -30% from a year earlier and +69% from the quarter before. Operating margin was -48.9%, net loss $104M (46.1% of revenue).
Ionis Pharmaceuticals, Q4 2024: revenue $227M (-30% year over year), operating margin -48.9%, net loss $104M, operating cash flow −$116M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $227M | +69% | -30% |
| Operating profit | −$111M | — | — |
| Net earnings | −$104M | — | — |
| Operating cash flow | −$116M | — | — |
What changed
Revenue was $226.6M in Q4 2024, down 30% year over year and up 69% from the previous quarter. Collaborative Agreement Revenue was the largest line at 43% of revenue.
Operating costs exceeded revenue by $110.8M, an operating margin of -48.9%. Total costs grew 2% against a revenue fall of 30%. The fastest-growing cost line was Cost of revenue (+25%). The quarter ended with a net loss of $104.3M, narrower than the previous quarter's $140.5M loss.
Operating cash flow was −$116.1M. Non-cash charges added back $2.7M of depreciation and amortization and $36.1M of share-based compensation. Working capital and other items used $50.6M. Capital expenditures of $25.5M exceeded it, leaving free cash flow of −$141.6M.
Questions
What was Ionis Pharmaceuticals' revenue in the fourth quarter 2024?
Ionis Pharmaceuticals (IONS) reported revenue of $227M for the fourth quarter 2024 (Q4 2024), -30% from a year earlier and +69% from the quarter before.
Was Ionis Pharmaceuticals profitable in the fourth quarter 2024?
Operating loss was $111M (-48.9% of revenue) and net loss $104M.